18F-JR1004 material

18F-JR1004 material

1. Drug name (generic name, chemical name, English name, Pinyin, if there is a customized name, the basis of naming should be explained)

common name:

18F-JR1004

chemical name:

N-[4-(diethylamino)benzyl]-N-[4-(2-(fluoro-18F)ethoxy)phenyl]-3,5-dimethoxyaniline

pin yin:

18F-JR1004

 

2. Chemical structure, molecular weight and molecular formula of drugs

chemical constitution:

18F-JR1004

 

 

3. Basis of the topic (literature on the development and application of this product at home and abroad)

Pancreatic ductal adenocarcinoma (PDAC) is the most common subtype of pancreatic cancer, accounting for over 90% of all pancreatic cancer cases. Due to its subtle early symptoms, lack of effective screening methods, and highly invasive biological characteristics, PDAC is often diagnosed at an advanced stage, leading to a 5-year survival rate of less than 10%. Traditional diagnostic methods, such as imaging studies (CT, MRI, etc.) and tumor marker tests (CA19-9, etc.), can assist in diagnosis to some extent but still have limitations in early detection and accurate assessment of the tumor. Therefore, developing molecular imaging techniques that enable early diagnosis and precise staging is crucial for improving the prognosis of PDAC patients. In recent years, the rapid development of molecular imaging technology has provided new tools for precise diagnosis and therapeutic monitoring of tumors. Positron emission tomography (PET) is an advanced medical imaging technique that allows us to see internal activities in a unique way. PET imaging technology, with its high sensitivity, functional imaging, whole-body scanning, high resolution, quantitative analysis, non-invasiveness, multimodal imaging, and broad clinical applications, has become an indispensable diagnostic and research tool in modern medicine. It not only enables early detection and accurate diagnosis of diseases but also provides important evidence for the formulation of treatment plans and evaluation of treatment efficacy.

Cannabinoid receptor type 2 (Cannabinoid Type 2 Receptor, CB2R), as a member of the G protein-coupled receptor family, is significantly upregulated in many tumors including PDAC. Studies have shown that CB2R plays an important role in the occurrence, development and metastasis of PDAC, which may become a potential diagnostic and therapeutic target.

The development of PET probes based on CB2R offers a new direction for molecular imaging of PDAC. By specifically binding to CB2R, these probes can detect the biological behavior of tumors with high sensitivity in vivo, providing crucial information for early diagnosis, staging, treatment response assessment, and prognosis prediction of PDAC. Moreover, PET imaging targeting CB2R may also serve as a basis for personalized therapy of PDAC, such as screening patients suitable for cannabinoid treatment by evaluating the expression level of CB2R. This paper aims to explore the biological role of CB2R in PDAC and its potential as a molecular imaging target, and to review the application prospects of CB2R-based PET probes in the diagnosis and treatment of PDAC, with the hope of offering new ideas and strategies for precision medicine in PDAC.

 

4. Research methods, experimental conditions and other data of target organs and whole body imaging or simulated clinical function measurement tests of experimental animals, and imaging or functional measurement results observed at various phases of the test

 

I. Whole body imaging and delayed imaging of experimental animals

1. Materials and methods

1.1 Experimental animals

The experimental animals were two mice with a weight of about 25g and male, obtained from the laboratory of Zhejiang University. Images were collected at multiple time periods after drug injection to obtain the distribution map of the drug in the body. After imaging, the experimental animals gradually woke up and returned to normal, with good diet, urine and feces, and mental state.

The figure below shows the 30min imaging image

 

 

5. Instructions for drugs

Generic name: 18F-JR1004

chemical name:

N-[4-(diethylamino)benzyl]-N-[4-(2-(fluoro-18F)ethoxy)phenyl]-3,5-dimethoxyaniline

pin yin:

18F-JR1004

[shape and properties]

This product is a colorless clear or slightly yellow clear solution.

[indication]

18F-JR1004 is used for tumor diagnosis and staging evaluation, cardiovascular disease imaging, bone lesion or bone metastasis monitoring, etc

[18F-JR1004 PET/CT brain imaging process]

Preparation before the examination

Fasting requirements: The examinee should fast for 4-6 hours (water is allowed) to avoid blood glucose fluctuations that interfere with the distribution of imaging agents.

Blood glucose monitoring: blood glucose should be tested before injection, usually requiring control of less than 11mmol/L.

Disinfection adjustment: suspend drugs that may interfere with the results (such as insulin, hormone drugs), and avoid strenuous exercise.

Imaging agent injection and resting period

Intravenous injection: 18F-JR1004 tracer was injected intravenously, and the dose was adjusted according to body weight and purpose of examination.

Resting waiting: Rest in a quiet, dark environment for 45-60 minutes after injection, during which avoid activity or mental stimulation to ensure the specific distribution of the tracer in brain tissue.

Brain imaging scan

Position fixation: the patient lies on the scanning bed, and the head is fixed with a special head support to keep breathing stable and body still.

CT scan: A low-dose CT scan (about 10 minutes) is performed first to obtain images of the brain's anatomical structure.

PET scan: A PET scan (about 20-30 minutes) was performed to detect the metabolic distribution and targeted binding of 18F-JR1004.

Image processing and diagnosis

Data fusion: PET functional images and CT anatomical images are fused through software to generate 3D brain metabolic imaging.

Clinical interpretation: The nuclear medicine physician issues a diagnosis report based on metabolic activity, lesion location and patient history.

Precautions after examination

Radiation protection: it is recommended to drink more water and urinate more after examination to accelerate the excretion of radioactive tracer.

Results obtained: The official report is usually received within 1-2 working days.

Follow-up: 18F-JR1004 and 18F-FDG brain imaging should be spaced at least 10 half-lives (or 20 hours).

This product is only for use in medical units with a radioactive Drug Use License.

[untoward effect]

Not yet found.

[taboo]

Not yet found.

[matters need attention]

If the product changes color or becomes cloudy, stop using it.

This product is only for use in medical units with a radioactive Drug Use License.

[Pregnant and lactating women]

Pregnant and lactating women are prohibited from using.

[Medication for children]

Reduce the dose appropriately according to body weight.

[specifications]

0.37~7.40GBq。

[Storage and packaging]

This product is sealed in a 30ml vial and placed in a lead container.

[term of validity]

The time from calibration is calculated as 6 hours.

[production unit]

Name: Hangzhou Jirui Technology Co., LTD

Address: Fengqigu Yunzhang Industrial Park, No.319 Shenjia Road, Gongshu District, Hangzhou City

Zip code: 234122

Phone number: 0571-87701916